14 citations,
March 2010 in “Gynecological endocrinology” New treatments for excessive hair growth in women include insulin modulators and enzyme inhibitors.
11 citations,
May 2003 in “Obstetrics and gynecology (New York. 1953. Online)/Obstetrics and gynecology” Hirsutism in women often indicates a hormonal imbalance and can be managed with a combination of hormonal treatments and hair removal methods.
10 citations,
February 2013 in “British Journal of Dermatology” Thyrotropin-releasing hormone may help control skin and hair growth and could aid in treating related disorders.
10 citations,
January 2003 in “Seminars in reproductive medicine” The article explains how to identify and treat excessive hair growth in women, which can be distressing and may signal other health problems.
9 citations,
December 2014 in “British Journal of Dermatology” Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
9 citations,
October 2012 in “Frontiers of Hormone Research” Antiandrogens are the main treatment for hirsutism, with individualized care and safe, affordable options needed.
6 citations,
August 2020 in “JCRPE” A boy with a rare form of early puberty caused by a new gene mutation responded well to treatment aimed at reducing testosterone and preserving adult height.
Finding functions for unknown GPCRs is hard but key for making new drugs.
Spironolactone with an oral contraceptive improved hair growth in women with hirsutism.
254 citations,
September 2014 in “Menopause” The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.
176 citations,
January 2003 in “Journal of Investigative Dermatology” Bone Morphogenetic Proteins (BMPs) help control skin health, hair growth, and color, and could potentially be used to treat skin and hair disorders.
173 citations,
May 2001 in “Human reproduction update” Oestrogens are key for bone growth during puberty in both boys and girls.
169 citations,
August 2004 in “Baillière's best practice & research. Clinical obstetrics & gynaecology/Baillière's best practice and research in clinical obstetrics and gynaecology” Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.
159 citations,
July 2006 in “Endocrine Reviews” Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.
86 citations,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
78 citations,
November 2008 in “Fertility and Sterility” Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.
66 citations,
September 2008 in “Dermatologic therapy” The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.
54 citations,
May 2017 in “Biomedicine & Pharmacotherapy” Edible seeds from the Cucurbitaceae family like pumpkin and watermelon seeds are nutritious and may have health benefits, but eating too much can cause side effects.
49 citations,
January 2010 in “International Journal of Pediatric Endocrinology” The document concludes that Nonclassic Congenital Adrenal Hyperplasia requires personalized treatment plans to manage symptoms and fertility, with glucocorticoids being a common therapy.
48 citations,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
36 citations,
November 2009 in “Journal of Investigative Dermatology” Prolactin may affect hair growth differently based on gender and scalp area.
30 citations,
July 2004 in “Fertility and Sterility” Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.
30 citations,
April 1997 in “European journal of endocrinology” The document concludes that managing hirsutism involves identifying the cause, using a scoring system for severity, combining cosmetic and medical treatments, encouraging weight loss, and providing psychological support, while noting the need for more research on drug treatments.
25 citations,
May 2021 in “Journal of exposure science & environmental epidemiology/Journal of exposure science and environmental epidemiology” Common Black hair care products may affect hormone levels and potentially impact health, especially in reproductive and metabolic areas.
25 citations,
May 2016 in “Progress in Biophysics & Molecular Biology” R-spondins and their receptors help increase bone growth and may be used to treat bone loss diseases.
23 citations,
October 2018 in “Australasian Journal of Dermatology” The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.
22 citations,
June 2012 in “PLOS ONE” Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.
22 citations,
January 2002 in “Treatments in endocrinology” Birth control pills help treat skin and hair growth problems linked to high male hormone levels.
19 citations,
September 2004 in “Reviews in gynaecological practice” Effective hirsutism management requires identifying the cause, combining new and traditional treatments, and setting realistic expectations for patients.
15 citations,
August 2021 in “Reviews in endocrine and metabolic disorders” COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.